NCT06799715

Brief Summary

This project aims to compare the acute metabolic effects of the three sweeteners sucrose, glucose, and fructose on GI hormones (GLP-1, PYY, CCK, and ghrelin). Furthermore, glycemic control, erythritol and xylitol concentrations, blood coagulation function , blood lipids, uric acid, high-sensitive C-reactive protein (hsCRP), complete blood count, gastric emptying, appetite-related sensations, and GI symptoms will be investigated.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
4mo left

Started Feb 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Feb 2025Sep 2026

First Submitted

Initial submission to the registry

January 23, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 29, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

February 6, 2025

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

1.6 years

First QC Date

January 23, 2025

Last Update Submit

April 30, 2026

Conditions

Outcome Measures

Primary Outcomes (4)

  • Effect of sucrose, glucose, fructose, and water on the GI hormone response - GLP-1

    Plasma GLP-1 will be measured with a commercially available immunoassay kit (MILLIPLEX® MAP; Millipore Corporation, Billerica, MA, USA).

    Blood will be drawn at the following timepoints: : -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration)

  • Effect of sucrose, glucose, fructose, and water on the GI hormone response - PYY

    PYY-3-36 will be quantified using a non-radioactive high sensitive sandwich ELISA (Millipore - # EZHPYYT66K).

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effect of sucrose, glucose, fructose, and water on the GI hormone response - CCK

    Plasma cholecystokinin (CCK) levels will be measured with a sensitive radioimmunoassay using a highly specific antiserum (No. 92128)

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effect of sucrose, glucose, fructose, and water on the GI hormone response - Ghrelin

    Octanoylated ghrelin will be measured by a radioimmunoassay with 125I \[Tyr24\] human ghrelin as tracer and a rabbit antibody against human ghrelin (final dilution 1/100000), which does not cross-react with desoctanoylated ghrelin.

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

Secondary Outcomes (16)

  • Effects on glycemic control - plasma glucose

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effects on glycemic control - plasma insulin

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effects on glycemic control - plasma c-peptide

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effects on glycemic control - plasma glucagon

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • Effects on erythritol concentrations

    Blood will be drawn at the following time points: -10 and -1 minutes (before administration) and 15, 30, 45, 60, 90, 120, and 180minutes (after administration).

  • +11 more secondary outcomes

Study Arms (4)

Sucrose

ACTIVE COMPARATOR

20 volunteers receive 33.5g sucrose dissolved in 300mL water as a drink.

Dietary Supplement: Sucrose

Glucose

ACTIVE COMPARATOR

20 volunteers receive 33.5g glucose dissolved in 300mL water as a drink.

Dietary Supplement: Glucose

Fructose

ACTIVE COMPARATOR

20 volunteers receive 33.5g fructose dissolved in 300mL water as a drink.

Dietary Supplement: Fructose

Water

PLACEBO COMPARATOR

20 volunteers receive 300mL water as a drink.

Dietary Supplement: Water

Interventions

SucroseDIETARY_SUPPLEMENT

33.5g sucrose dissolved in 300mL tap water

Also known as: Saccharose
Sucrose
GlucoseDIETARY_SUPPLEMENT

33.5g glucose dissolved in 300mL tap water

Also known as: Dextrose
Glucose
FructoseDIETARY_SUPPLEMENT

33.5g fructose dissolved in 300mL tap water

Fructose
WaterDIETARY_SUPPLEMENT

300mL water

Water

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, non-diabetic (glycated hemoglobin (HbA1c) \< 5.7%, fasting glucose \< 5.6 mmol/L), and normal weight participants with a body-mass index (BMI) of 19.0-24.9 kg/m2, parameters of complete blood count within normal range
  • Age 18-55 years
  • Stable body weight (± 5%) for at least three months
  • Able to give informed consent as documented by signature

You may not qualify if:

  • Fructose intolerance
  • Any pre-existing diet (e.g., vegetarian diet, vegan diet, sugar free diet, paleo diet, Atkins diet, ketogenic diet) that deviates from normal eating habits
  • Regular consumption (\>1/ week) of erythritol or xylitol
  • Regular intake of medications, except contraceptives
  • Pre-existing impairment of blood coagulation/thrombocyte function (e.g. hereditary, regular intake of anti-coagulant agents (e.g. NSAIDs, heparin, warfarin, etc.))Chronic or clinically relevant acute infections/diseases
  • Substance abuse (more than 1 glass wine/beer per day; regular consumption of cannabis, consumption of cocaine, heroin, etc.), regular smoking
  • Pregnancy: although no contraindication, pregnancy might influence metabolic state. Women who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening.
  • Shift worker
  • Participation in another study with investigational drug within the 30 days preceding and during the present study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Claraspital

Basel, 4002, Switzerland

Location

MeSH Terms

Interventions

SucroseGlucoseFructoseWater

Intervention Hierarchy (Ancestors)

DisaccharidesOligosaccharidesPolysaccharidesCarbohydratesSugarsHexosesMonosaccharidesKetosesHydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Officials

  • Anne Christin Meyer-Gerspach, PD, PhD

    St. Clara Research Ltd.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2025

First Posted

January 29, 2025

Study Start

February 6, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations